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Abstract
Introduction: This 28-week, phase IIIb study assessed safety and maintenance of response to certolizumab pegol (CZP) in
a diverse population of rheumatoid arthritis (RA) patients, stratified by prior anti-TNF exposure, concomitant methotrexate
(MTX) use and disease duration. The ability to predict achievement of low disease activity (LDA) at week 28 from
improvements in Disease Activity Score 28 (DAS28), erythrocyte sedimentation rate (ESR), swollen joint count (SJC) and
Clinical Disease Activity Index (CDAI) up to week 12 was assessed.
Methods: The 28-week study population included all patients who completed the double-blind (DB) phase and entered
the open-label (OL) phase, receiving 200 mg CZP every 2 weeks (Q2W) ≥16 weeks. In the 12-week DB period, patients
with active RA and an inadequate response to ≥1 disease-modifying antirheumatic drug (DMARD) were randomized 4:1
to CZP (400 mg at weeks 0, 2 and 4 then 200 mg Q2W) or placebo (Q2W), stratified by prior anti-TNF use, concomitant
use of MTX and disease duration (<2 years vs. ≥2 years).
Results: A total of 955 patients entered the OL phase. At week 28, similar clinical improvements were seen in those
receiving CZP throughout (CZP→ CZP; n = 771) and those receiving placebo during the DB phase and switching to CZP
in the OL phase (placebo→ CZP; n = 184) (ACR20 response rate = 59.7 % vs. 53.3 %; ACR50/ACR70 response rates were
also similar). Effect of CZP treatment was similar regardless of prior anti-TNF use, disease duration and concomitant
DMARDs, based on ACR20 response rates. The percentage of patients achieving DAS28(ESR) LDA at week 28 was
calculated for DAS28(ESR), SJC or CDAI responders at earlier time points. Reductions from baseline (Δ) of DAS28(ESR) <1.2,
ΔSJC <25 % or ΔCDAI <10 by week 12 were associated with <9 % chance of achieving LDA at week 28 regardless of
prior anti-TNF exposure. Adverse event rates were similar for placebo→ CZP and CZP→ CZP patients, with no new safety
signals identified.
Conclusions: A diverse population of RA patients with varying disease duration showed rapid and sustained clinical
improvements on CZP treatment, regardless of prior anti-TNF or concomitant DMARD use. Failure to achieve
improvements in DAS28(ESR), SJC or CDAI within the first 12 weeks of CZP therapy was associated with a low chance of
achieving LDA at week 28. No new safety signals were observed.
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Introduction
Study populations in conventional clinical trials for anti-
tumor necrosis factor (TNF) agents in rheumatoid arth-
ritis (RA) have comprised a largely homogeneous patient
group with high disease activity and no prior anti-TNF
experience, reflecting a small proportion of patients in
routine clinical care [1–5]. While such trials demon-
strate the ability of anti-TNFs to slow radiographic pro-
gression and improve the signs and symptoms of RA in
patients with active disease, studies which permit the in-
clusion of more diverse patient groups such as those
with and without prior anti-TNF use, with and without
baseline methotrexate (MTX) use or with prior exposure
to non-MTX conventional synthetic disease-modifying
antirheumatic drugs (csDMARDs) would more accur-
ately reflect patients in real-world clinical care. The
REALISTIC trial is one such study, from which the effi-
cacy of certolizumab pegol (CZP) after 12 weeks of
treatment in a heterogeneous population of RA patients
has previously been reported [6]. Following the 12-week
double-blind (DB) period, the REALISTIC study in-
cluded a 16-week open-label extension (OLE) period, in
order to assess the efficacy and safety of CZP as an add-
on therapy to current treatment in this varied population
relevant to clinical care, over a 28-week period.
Here we report the safety and key secondary out-
comes, including maintenance of response to certolizu-
mab pegol (CZP) in this heterogeneous population of
RA patients, stratified by prior exposure to anti-TNFs,
concomitant MTX use and disease duration. In addition,
the results of exploratory analyses are reported, investi-
gating whether lack of response during the first 12 weeks
of treatment (based on the timing and magnitude of the
change in Disease Activity Score based on 28 joints and
erythrocyte sedimentation rate [DAS28(ESR)], swollen
joint count [SJC] or Clinical Disease Activity Index
[CDAI]), predicts failure to achieve low disease activity
(LDA) at week 28 in this diverse patient population.
Early prediction of clinical outcomes allows identifica-
tion of a time at which it might be appropriate to stop
therapy in patients failing to respond to CZP and could
allow an earlier change to a more appropriate treatment
option, resulting in faster improvements in patient out-
comes and potentially better cost efficiency for the
health care system. It has been previously reported in
the RAPID 1 trial for CZP that a lack of improvement in
DAS28(ESR) by week 12 in RA patients predicted failure
to achieve LDA at later time points [7].
Methods
Full inclusion and exclusion criteria were reported in
the primary publication [6]. Briefly, eligible patients
were ≥18 years of age, had adult-onset RA for ≥3
months as defined by the 1987 American College of
Rheumatology (ACR) criteria, and showed an unsatis-
factory response or intolerance to ≥1 csDMARD [8].
Patients had active disease by ≥5 tender and ≥4 swollen
joints (TJC; SJC [28-joint count]) and either C-reactive
protein (CRP) ≥10 mg/l or ESR (Westergren method)
≥28 mm/h at screening. Biologic disease-modifying
antirheumatic drugs (bDMARDS) were discontinued
before study entry; patients were excluded if previously
treated with >2 anti-TNFs, rituximab or abatacept.
Analgesics, nonsteroidal anti-inflammatory drugs
(NSAIDs), oral corticosteroids (10 mg/day prednisone
equivalent) and csDMARDs, MTX, leflunomide, sulfa-
salazine, chloroquine, hydroxychloroquine, azathio-
prine and gold were permitted if doses were stable
prior to baseline. Exclusion criteria included any other
inflammatory arthritis or a history of chronic, serious
or current infection (including evidence of latent tu-
berculosis [TB] defined as a positive purified protein
derivative skin test [≥5 mm] or close contact with indi-
viduals with active TB). Patients positive for purified
protein derivative could be included if active TB was
ruled out and if they were adequately treated for la-
tent TB (e.g., isonicotinic acid hydrazide), with treat-
ment initiated at least 1 month before first administration
with the study drug.
Study design
This 28-week, phase IIIb study (NCT00717236) consisted
of a 12-week, randomized, DB period and a subsequent
16-week OL phase. Patients were recruited from 230 cen-
ters in the USA and Canada (75 %), and Europe (25
%). The study protocol was approved by the Institutional
Review Board/Independent Ethics Committee as defined
in local regulations and performed according to the Dec-
laration of Helsinki (please see Acknowledgements for a
complete list of ethics committees that approved this
study). All patients provided written consent. Sample size
was selected to provide at least 90 % power to show a
statistically significant difference between the active and
placebo groups at week 12 in both the primary outcome
(ACR20 response rate) and also subgroup analyses (prior
anti-TNF usage; concomitant MTX treatment and disease
duration).
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Fig. 1 a REALISTIC trial design. b Subject disposition. aDB phase. bOne week 12 CZP completer discontinued after week 12 due to an AE, did not
receive any study medication in the OL phase, and was not included in the OL analysis set. AE adverse event, CZP certolizumab pegol, DMARD
disease-modifying antirheumatic drug, OLE open-label extension, Q2W every other week
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During the initial 12-week period patients were ran-
domized 4:1 by means of an interactive voice response
system to either 400 mg CZP at weeks 0, 2 and 4
followed by 200 mg CZP every 2 weeks (Q2W) (CZP pa-
tient group), or placebo (0.9 % saline) Q2W (placebo
group), stratified by prior anti-TNF use, concomitant use
of MTX and disease duration (<2 years vs. ≥2 years) to
ensure balanced treatment assignments [6]. Patients who
had completed 12 weeks of treatment with either 200
mg CZP Q2W or placebo were eligible to receive OL
CZP 200 mg Q2W for ≥16 weeks (Fig. 1a). Results from
the 16-week OL phase are reported here, together with
the association between DAS28(ESR) low disease activity
at week 28 and failure to achieve early responses.
Efficacy and safety evaluations
Efficacy and safety evaluations were performed every 8
weeks until patient completion or withdrawal from the
study. The primary endpoint of the study was ACR20 re-
sponse rate at week 12 [6]. Secondary endpoints included
efficacy measurements (ACR20/ACR50/ACR70 response
rates, DAS28[CRP], Health Assessment Questionnaire-
Disability Index [HAQ-DI], Clinical Disease Activity Index
[CDAI] and Simplified Disease Activity Index [SDAI]) at
week 12 and throughout the OLE.
Post hoc analyses included week 28 ACR20, ACR50
and ACR70 response rates stratified by prior anti-TNF
use, and week 28 ACR20 response rates stratified by
number and type of concomitant DMARDs at baseline,
baseline MTX use, disease duration and rheumatoid
factor (RF) titer at baseline. Post hoc analyses to predict
the proportion of CZP-treated patients who achieved
DAS28(ESR) LDA (≤3.2) at week 28 based on early re-
sponses were also conducted, stratified by prior anti-
TNF experience. Failure to achieve LDA was predicted,
based on the timing and magnitude of nonresponse in
patients who did not achieve a reduction of <0.6, <1.2
and <1.8 units from baseline in DAS28(ESR) or SJC per-
centage reduction of <10 %, <25 % and <50 % from base-
line or reduction of <10 CDAI from baseline at any time
‘up to’ and ‘at’ weeks 2, 6, or 12.
Adverse events (AEs) were recorded at each visit. Any
events meeting the regulatory definition of a serious AE
(SAE) [9], all opportunistic infections, malignancies (ex-
cluding some basal cell carcinomas at the discretion of
the investigator) and any medical event assessed as being
relevant by the investigator, including events that did
not require hospitalization, were considered SAEs.
Statistical analysis
Efficacy analyses up to week 28, and safety evaluations
from week 12 up to 28, were performed on the OL set,
comprising all patients who completed 12 weeks of
treatment in the DB phase and who received ≥1 dose of
OL CZP. ACR response rates were determined using
nonresponder imputation (NRI) when patients withdrew
for AE or lack or loss of efficacy, and last observation
carried forward (LOCF) in case of any other reason. Least
squares means (change from baseline) in DAS28(CRP),
SJC and HAQ-DI were analyzed using a mixed-effects
model for repeated measures (MMRM) to estimate re-
sponse, which included terms for visit, visit by treat-
ment interaction and baseline response (for the
respective endpoint) by visit interaction. Predictability
analyses by early changes in DAS28(ESR), SJC and
CDAI were conducted using observed data (from the
OL set); data for DAS28(ESR) were also analyzed using
LOCF-imputed data from the full analysis set (FAS)
(comprising all patients who received ≥1 dose of CZP).
If all weeks prior to the specified time point were miss-
ing, the patient was not counted. Failure to achieve the
specified reductions in DAS28(ESR), SJC and CDAI
was defined as (percentage) change from baseline less
than the cut point at every visit up to and including the
time point under analysis. Predictability analyses by
DAS28(ESR) nonresponse ‘at’ (as opposed to ‘up to’)
the relevant time point were also conducted using
LOCF-imputed data from the FAS. Out of the above
defined populations, the number (percentage) of pa-
tients achieving LDA at week 28 is presented.
Results
Patients
A total of 1,063 patients were randomized into the DB
phase of the study; 851 and 212 patients in the CZP and
placebo groups, respectively. A total of 955 patients
completed this 12-week phase and entered the OL
phase; 771 (90.6 %) of the CZP group and 184 (86.8 %)
of the placebo group (Fig. 1b). Of these, 809 (84.7 %)
remained in the study until week 28. The median num-
ber of doses received during the OL phase alone, not in-
cluding prior exposure during the DB phase, was 8
(range 1–21) for placebo→CZP patients and 8 (range
1–32) for CZP→CZP patients.
Patient demographics, baseline disease characteris-
tics and prior and concomitant therapies were similar
between placebo and CZP patients randomized in the
DB phase [6] (and the placebo→ CZP and CZP→ CZP
groups at entry to the OL phase (Table 1). Additionally,
characteristics including age, disease duration and dis-
ease activity (measured by HAQ-DI, DAS28[ESR] and
DAS28[CRP]) were similar when patients were strati-
fied by prior anti-TNF use, concomitant MTX use at
baseline and disease duration. The overall proportion
of patients with prior anti-TNF use was similar in the
patients present at entry into the DB phase and at the
start of OL phase of the study (37.6 % vs. 37.4 %,
respectively).
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Treatment efficacy
The rapid improvements seen in patients receiving CZP
therapy during the first 12 weeks of treatment [6] (as
measured by ACR20 response rate) were maintained to
week 28 (Fig. 2a; Table S1 in Additional file 1). Addition-
ally, in the placebo patients switching to CZP following
entry into the OL phase, rapid clinical improvements
were seen: by week 20 (8 weeks after OLE entry)
placebo→ CZP patients showed similar ACR20 response
rates to CZP→ CZP patients (placebo→ CZP: 58.7 %;
CZP→ CZP: 59.6 %), which were maintained to week 28
(placebo→ CZP: 53.3 %; CZP→CZP: 59.7 %). At this
time point, placebo→CZP patients and CZP→ CZP pa-
tients also showed similar ACR50 and ACR70 response
rates (Fig. 2b; Table S1 in Additional file 1), improve-
ments in DAS28(CRP) (Fig. 2c; Table S1 in Additional
file 1), and improvements in physical function (Fig. 2d;
Table S1 in Additional file 1).
Post hoc analyses by patient subgroups
At week 28, patients stratified by prior and non-prior anti-
TNF use showed similar ACR20, ACR50 and ACR70 re-
sponse rates in the placebo→CZP and CZP→CZP
groups, although there was a numerical trend for slightly
higher response rates in the anti-TNF naïve patients
(Fig. 3a). ACR20 response rates in patients with vs. with-
out prior anti-TNF were 55.2 % vs. 62.4 % for CZP→CZP
patients and 54.9 % vs. 52.2 % for placebo→CZP patients;
ACR50 response rates in patients with vs. without prior
anti-TNF were 30.4 % vs. 39.3 % for CZP→CZP patients
and 25.4 % vs. 34.5 % in placebo→CZP patients). Patients
with and without prior anti-TNF use also experienced
similar improvements in DAS28(CRP) (Fig. 3b; Table S1
in Additional file 1). ACR20 response rates were also gen-
erally similar in the placebo→CZP and CZP→CZP
groups when patients were stratified by the number and
type of concomitant DMARDs used (0 vs. 1 vs. ≥2
DMARDs; with vs. without MTX use at baseline) (Fig. 3c),
although with a trend for numerically higher response
rates in patients receiving concomitant DMARD therapy
compared to CZP monotherapy (Fig. S1 in Additional
file 1). Stratifying patients by their disease duration (<2 vs.
≥2 years) also showed similar response rates. (Fig. 3d). Fi-
nally, a trend for improved ACR20 response rates with in-
creasing baseline RF levels (<14 IU/mL (upper limit of
normal), 14–50 IU/mL (approximately 3× upper limit of
normal [ULN]) and >50 IU/mL) was observed (Fig. S2 in
Additional file 1).
Safety up to week 28
During the DB phase of the study the incidence of AEs
and SAEs in the placebo and CZP groups were similar,
as reported previously [6], and shown in Table 2. In the
OL phase of the study, similar incidences of AEs were
reported in placebo→CZP and CZP→CZP patients
(77.2 % vs. 67.7 %). The most frequently reported AEs
were upper respiratory tract infection, urinary tract in-
fection and flare of RA (Table 3).
During the OL phase, four of the placebo→CZP pa-
tients (2.2 %) and 29 (3.8 %) of the CZP→CZP patients
withdrew from the study due to AEs. The most common
AEs leading to withdrawal were Herpes zoster infections
Table 1 Demographics and disease characteristics at baseline of
the double-blind phase (OL set)
OL set
Placebo→ CZPa CZP→ CZPa
(n = 184) (n = 770)
Age (years), mean (SD) 53.7 (12.7) 55.3 (12.3)
Gender, % female 79.3 77.9
Disease duration (years), mean (SD)b 8.9 (9.0) 8.5 (8.7)
Disease duration <2 years, n (%) 45 (24.5) 184 (23.9)
Tender joint count, mean (SD) 14.7 (6.4)
(n=184)
14.7 (6.5)
(n=769)
Swollen joint count, mean (SD) 11.1 (5.1)
(n=184)
11.8 (5.5)
(n=769)
DAS28(CRP), mean (SD) 5.7 (0.8)
(n=183)
5.7 (0.9)
(n=768)
DAS28(ESR) 6.4 (0.8)
(n=183)
6.4 (0.9)
(n=767)
<3.2, n (%) 0 0
3.2–5.1, n (%) 11 (6.0) 68 (8.9)
>5.1, n (%) 172 (94.0) 699 (91.1)
HAQ-DI, mean (SD) 1.6 (0.6) 1.5 (0.6)
CRP (mg/L), median (min, max) 10.0 (2.9, 159.0) 9.0 (1.0, 164.0)
Rheumatoid factor positive (≥14 IU/mL),
n (%)
127 (77.0)
(n=165)
505 (73.9)
(n=683)
Treatment history, n (%)
Prior DMARD use 115 (62.5) 514 (66.8)
Prior anti-TNF 71 (38.6) 286 (37.1)
Prior anti-TNF/other biological use 76 (41.3) 309 (40.1)
Other prior medicationsc 51 (27.7) 209 (27.1)
Concomitantd medications
DMARDs 152 (82.6) 649 (84.3)
MTX 128 (69.6) 533 (69.2)
Other medicationsc 184 (100) 768 (99.7)
OL open-label, CZP certolizumab pegol, DAS28 Disease Activity Score in 28
joints, CRP C-reactive protein, ESR erythrocyte sedimentation rate, HAQ-DI
Health Assessment Questionnaire-Disability Index, DMARD disease-modifying
antirheumatic drug, TNF tumor necrosis factor, MTX methotrexate
aPatients who completed 12 weeks of treatment with either CZP 200 mg every
other week (Q2W) or placebo during the double-blind phase entered the OL
phase and subsequently received active treatment (CZP 200 mg Q2W)
bDuration at screening visit
cMedications other than DMARDs, anti-TNFs or other biologics, including those
for treatment of comorbidities
dConcomitant medications include those ongoing at the week 12 visit or taken
during the OLE phase
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(two patients overall; 0.2 %), rheumatoid arthritis (two
patients; 0.2 %) and respiratory tract small cell carcin-
omas (two patients; 0.2 %). Injection and infusion site
reactions occurred in 4.9 % of CZP→CZP patients and
1.8 % of placebo→CZP patients; there were no inci-
dences of serious infusion site reactions.
SAEs were experienced by 11.4 % of patients in the
placebo→ CZP group and 7.3 % of patients in the
CZP→ CZP group during the OL phase, the most com-
mon of which were lower respiratory tract and lung in-
fections, reported by four patients (2.2 %) and seven
patients (0.9 %) in the placebo→CZP and CZP→CZP
groups, respectively. There were no reported cases of tu-
berculosis or other opportunistic infections. There was
one death in the CZP→ CZP group (due to small cell
lung cancer) and one death in the placebo→ CZP group
(myocardial infarction).
Predictability analyses
Predictability of achieving LDA by cumulative nonresponse
in DAS28(ESR), CDAI, and SJC up to week 12
At week 28, 225 patients (27.4 %) from the FAS achieved
DAS28(ESR) LDA. Failure to achieve LDA was associ-
ated with the timing of nonresponse (as measured by
DAS28(ESR), CDAI and percentage change in SJC) up
to week 12 (Table 4). Reductions in DAS28(ESR) of <1.2
up to weeks 2, 6 and 12 were associated with a chance
of LDA at week 28 of 24.8 %, 16.8 % and 5.4 %, respectively.
Similarly, SJC percentage changes of <25 % up to weeks 2,
6 and 12 were associated with a chance of LDA at week 28
of 20.7 %, 11.9 % and 5.9 %, respectively (at week 12, LS
mean change from baseline [standard error] SJC was −6.3
[0.20] in CZP patients, −3.9 [0.36] in placebo patients). The
same trend was seen based on early CDAI nonresponse: pa-
tients with CDAI reductions <10 by these time points had
Fig. 2 Treatment response to week 28. a ACR20 response rates up to week 28. b ACR50 and ACR70 response rates up to week 28 c DAS28(CRP)
change from baseline up to week 28. d HAQ-DI change from baseline up to week 28 (OL set, imputed data). Footnote: ACR response rates were
calculated using NRI if withdrawal was due to an AE or lack or loss of efficacy, and LOCF in case of any other reason. Least squares means
(change from baseline) in DAS28(CRP) and HAQ-DI were analyzed using MMRM. AE adverse event, CRP C-reactive protein, CZP certolizumab pegol,
DAS28 Disease Activity Score in 28 joints, HAQ-DI Health Assessment Questionnaire-Disability Index, LOCF last observation carried forward, MMRM
mixed-effects model for repeated measures, NRI nonresponder imputation, OL open-label
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25.3 %, 18.8 % and 7.1 % chance of LDA at week 28
(Table 4). Patients who did achieve a reduction from base-
line in DAS28(ESR) of ≥1.2, SJC ≥25 % or CDAI ≥10 at any
week up to week 12 had a higher chance of achieving week
28 LDA (35.6 %, 36.1 % and 34.1 %, respectively).
Failure to achieve LDA at week 28 was also associated
with the magnitude of early response. Patients who
failed to meet the lower thresholds for improvement had
a lower chance of achieving LDA at week 28: reductions
from baseline in DAS28(ESR) of <0.6, <1.2 and <1.8 up
to week 12 were predictive of a 2.4 %, 5.4 % and 13.0 %
chance of achieving LDA at week 28, respectively (Table
S2 in Additional file 1). Correspondingly, patients achiev-
ing <10 %, <25 % and <50 % reductions from baseline in
SJC had 7.4 %, 5.9 % and 13.9 % chance of week 28 LDA.
For any given threshold, the failure to respond by a later
time point was associated with a lower chance of achiev-
ing LDA at week 28. Similar trends were seen when LOCF
imputation was used to analyze data from the FAS (Table
S2 in Additional file 1).
Results were confirmed in sensitivity analyses, in
which DAS28(ESR) nonresponse was analyzed ‘at’, rather
than ‘up to’, each time point. The same trend was ob-
served: in CZP-treated patients, the percentage achieving
Fig. 3 Clinical response at week 28, stratified by baseline characteristics. a Week 28 ACR20/ACR50/ACR70 responses stratified by prior anti-TNF
therapy. b DAS28(CRP) progression up to week 28 by prior anti-TNF therapy. c Week 28 ACR20/ACR50/ACR70 responses stratified by baseline
DMARDs. d Week 28 ACR20/ACR50/ACR70 responses stratified by disease duration (OL set, imputed data). Footnote: ACR response rates were
calculated using NRI if withdrawal was due to an AE or lack/loss of efficacy, and LOCF in case of any other reason. Least squares mean (change
from baseline) in DAS28(CRP) was analyzed using MMRM. AE adverse event, CRP C-reactive protein, CZP certolizumab pegol, DAS28 Disease Activity
Score in 28 joints, LOCF last observation carried forward, MMRM mixed-effects model for repeated measures, NRI nonresponder imputation,
OL open-label, TNF tumor necrosis factor
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LDA at week 28 for any given threshold in DAS28(ESR)
was lower in nonresponders at later time points (Table
S3 in Additional file 1).
Predictability of achieving LDA stratified by prior anti-TNF
experience
The proportion of patients achieving a change from
baseline in DAS28(ESR) ≥1.2, SJC ≥25 % or CDAI ≥10
by week 12 was similar between patients who had re-
ceived prior anti-TNF therapy and those who had not
(Fig. 4). For any given threshold in DAS28(ESR), SJC or
CDAI, failure to respond up to a later time point was as-
sociated with a lower chance of achieving at week 28, re-
gardless of prior anti-TNF experience (Table 4).
Discussion
In a diverse group of patients with active RA, addition
of CZP to current therapy for up to 28 weeks was asso-
ciated with sustained improvements in disease activity
and physical function as measured by a variety of clinical
endpoints, including ACR20/ACR50/ACR70 response
rates, DAS28(ESR), DAS28(CRP), and HAQ-DI.
By week 20, patients who began receiving CZP at week
12 (following placebo treatment in the DB phase) showed
similar improvements in disease activity to those who had
received CZP since week 0. Both the onset and the magni-
tude of response were consistent with previous studies, in
which clinical benefits associated with CZP treatment
have been observed from week 1 following the com-
mencement of CZP therapy, both as a monotherapy (the
FAST4WARD study) [10], and in addition to MTX (the
RAPID 1 and 2 studies) [11, 12]. Sustained efficacy was
observed across all subgroups of CZP patients, including
those with and without prior anti-TNF use, receiving CZP
monotherapy or concomitant DMARDs (regardless of
type or number), with and without concomitant MTX use
at baseline, and with disease duration of < or ≥2 years.
This is in agreement with the DOSEFLEX study of CZP,
where CZP exhibited similar efficacy in RA patients with
or without prior exposure to anti-TNF agents over 34
weeks [13]. Previously published studies employing a
range of biologic agents have also demonstrated the effi-
cacy of this class of drug in RA patients who have previ-
ously shown inadequate responses to anti-TNF agents.
These include both TNF-targeting (golimumab) and non-
TNF-targeting (rituximab, tocilizumab, abatacept) therap-
ies [14–17]. Moreover, in the current study, there was a
suggestion of a possible correlation between improved
ACR20 response and increasing baseline RF levels, based
Table 2 Adverse events: overview of adverse events in the DB and OL phases
DB phase week 0 – week 12 OL phase week 12 – week 28
(Safety set) (OL set)
Placebo CZP Placebo→ CZPa CZP→ CZPa
(n = 209) (n = 846) (n = 184) (n = 770)
Any AE, incidence/100 pt-yrs (n, %) 483.2 (129, 61.7) 522.1 (571, 67.5) 328.9 (142, 77.2) 239.1 (521, 67.7)
Patients discontinuing due to AE, n (%) 8 (3.8) 40 (4.7) 3 (1.6) 26 (3.4)
Injection and infusion site reactions, incidence/100 pt-yrs (n, %) 4.2 (2, 1.0) 25.3 (49, 5.8) 8.8 (9, 4.9) 3.2 (14, 1.8)
Serious AEs, incidence/100 pt-yrs (n, %) 25.8 (12, 5.7) 26.7 (52, 6.1) 20.6 (21, 11.4) 13.0 (56, 7.3)
Serious infections, incidence/100 pt-yrs (n, %) 8.3 (4, 1.9) 11.1 (22, 2.6) 5.7 (6, 3.3) 4.1 (18, 2.3)
Deaths, n (%) 0 2 (0.2) 1 (0.5) 1 (0.1)
DB double-blind, OL open-label, CZP certolizumab pegol, AE adverse event, Pt-yrs patient-years, n number of patients reporting AE
aPatients who completed 12 weeks of treatment with either CZP 200 mg every other week (Q2W) or placebo during the double-blind phase entered the OL phase
and subsequently received active treatment (CZP 200 mg Q2W) for ≥16 weeks
Table 3 Adverse events: most common adverse events
reported in the OL phase
MedDRA v 9.0System organ
classHigh level term
OL phase week 12 – week 28
(OL set)
Placebo→ CZPa CZP→ CZPa
(n = 184) (n = 770)
Most common AEs, incidence/100 pt-yrs (n, %)b:
Infections and infestations 92.9 (73, 39.7) 79.4 (271, 35.2)
Nasopharyngitis 12.9 (13, 7.1) 9.3 (40, 5.2)
Sinusitis 10.8 (11, 6.0) 7.9 (34, 4.4)
Upper respiratory tract infection 16.0 (16, 8.7) 14.2 (60, 7.8)
Urinary tract infection 14.8 (15, 8.2) 11.9 (51, 6.6)
Musculoskeletal and connective tissue
disorders
47.4 (178, 23.1) 49.1 (227, 23.8)
Rheumatoid arthritis 18.0 (18, 9.8) 12.4 (53, 6.9)
Nervous system disorders 26.0 (25, 13.6) 15.6 (66, 8.6)
Headache 10.8 (11, 6.0) 5.5 (24, 3.1)
Skin and subcutaneous tissue disorders 33.3 (31, 16.8) 22.5 (93, 12.1)
Rash 10.9 (11, 6.0) 5.5 (24, 3.1)
OL open-label, CZP certolizumab pegol, AE adverse event, Pt-yrs patient-years,
n number of patients reporting AE
aPatients who completed 12 weeks of treatment with either CZP 200 mg every
other week (Q2W) or placebo during the double-blind phase entered the OL
phase and subsequently received active treatment (CZP 200 mg Q2W) for
≥16 weeks
bAEs occurring in ≥5 % of patients in either treatment group are presented
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Table 4 Proportion of CZP-treated patients achieving LDA at week 28. Predictability by change in DAS28(ESR), SJC and CDAI up to
the indicated week – overall population and by prior anti-TNF experience (OL set, observed data)
Shading represents ≤5.0 % of patients achieving LDA (DAS28[ESR] ≤3.2) at week 28
Numbers in brackets are the number of patients who achieved LDA at week 28, over the number of patients not achieving the SJC %, DAS28(ESR) or CDAI change
threshold at any week up to the week presented
CZP certolizumab pegol, OL open-label, LDA low disease activity, DAS28 Disease Activity Score in 28 joints, CRP C-reactive protein, SJC swollen joint count, CDAI
Clinical Disease Activity Index, TNF tumor necrosis factor, ESR erythrocyte sedimentation rate
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upon the observed data. Previous reports suggested that
RF negativity may be associated with greater response to
monoclonal anti-TNFs [18–20], but these findings have
been inconsistent, with other reports suggesting no strong
association [21]. This suggests that individual factors may
be insufficient to predict clinical response, and in future
the identification and validation of multifactorial “smart
biomarkers” may facilitate recognition of those patients
who are likely to have the desired clinical response, allow-
ing the most appropriate treatment options to be selected
[22].
The safety profile observed here was similar to previ-
ous CZP trials [10–12], but with no tuberculosis or op-
portunistic infections recorded. The safety profile was in
line with the anti-TNF class [23, 24]. No new safety sig-
nals were identified. The incidences of AEs and SAEs
were similar between the CZP and placebo groups dur-
ing the 12-week DB phase [6], and the CZP→CZP and
placebo→ CZP groups during the OL phase.
In this diverse patient population, the majority of patients
responded to treatment with CZP by week 12. Low chances
of achieving LDA at week 28 could be predicted for sub-
groups early in the course of CZP treatment based on the
timing and magnitude of the initial change in DAS28(ESR).
These data are in line with the post hoc analysis of the
RAPID 1 study of CZP in adult patients with active RA
despite MTX therapy, who received CZP 200 mg or 400
mg Q2W plus MTX [7]. These analyses demonstrated that
failure to achieve improvement in DAS28 within the first
12 weeks of CZP therapy was predictive of a low probability
of achieving LDA at year 1. Moreover, the percentage of pa-
tients achieving LDA at week 28 in subgroups of nonre-
sponders at early time points was found to be strongly
dependent on the magnitude and timing of the lack of the
response. This is in agreement with published studies of
other biologics, which report that failure to respond by later
time points (up to 26 weeks after commencing biologic
therapy) correlated with reduced likelihood of achieving
clinical endpoints. In the present study, a low percentage of
patients achieving LDA at week 28 could also be predicted
using either SJC or CDAI early nonresponses. Furthermore,
a lack of response up to week 12, as measured either by
change from baseline in DAS28(ESR) or CDAI, or percent-
age change from baseline in SJC, predicted failure to
achieve LDA at week 28 in both patients naïve to, and pre-
viously exposed to, anti-TNFs.
These data support the concept that a decision can be
made at week 12 regarding continuation of CZP treat-
ment. This is in line with the treat-to-target recommen-
dations, which state that until the desired treatment
target is reached, drug therapy should be adjusted at
least every 3 months [25].
Limitations of this study included the lack of radio-
graphic assessment, without which any joints swollen
due to factors other than structural damage could not be
detected. Furthermore, results are reported here up to
week 28 and longer-term data would be useful in ascer-
taining the maintenance of response. Predictability ana-
lyses were conducted using the OL set, comprising all
patients who received at least one dose of CZP in the
Fig. 4 Clinical improvements in CZP-treated patients to week 12,
stratified by prior-anti-TNF exposure. Cumulative proportion of CZP
patients achieving (a) ≥1.2 reduction from baseline in DAS28(ESR),
(b) ≥25 % change in baseline in SJC and (c) ≥10 reduction from
baseline in CDAI (FAS, LOCF imputation). Footnote: Patients could
achieve the response at any time point up to and including the
relevant week. If all prior weeks were missing the patient was not
counted. CDAI Clinical Disease Activity Index, CZP certolizumab
pegol, DAS28 Disease Activity Score in 28 joints, ESR erythrocyte
sedimentation rate, FAS full analysis set, LOCF last observation carried
forward, SJC swollen joint count, TNF tumor necrosis factor
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OL phase, and also using the FAS, comprising all pa-
tients who were administered at least one dose of CZP,
and which included 80 patients (9.4 %) who dropped out
of the study by week 12. While the predictive values ap-
peared similar when calculated either using LOCF im-
putation or an observed case analysis, both ways may
slightly bias the predicted response rates, and as such,
general trends may be of more clinical value than precise
figures.
Conclusions
In conclusion, the results of the REALISTIC study con-
ducted in patients reflective of real-world clinical care
demonstrate sustained improvements in disease activity
and physical functions following 28 weeks of CZP treat-
ment across this diverse population of RA patients, includ-
ing with and without prior anti-TNF use, on a variety of
concomitant DMARDs and regardless of disease dur-
ation (< and ≥2 years). Additionally, in patients both naïve
to and previously exposed to prior anti-TNFs, DAS28(ESR),
SJC or CDAI non-response at time points up to week 12
were predictive of a low probability of achieving LDA at
week 28.
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